24325-14-2

Basic information

• Product Name: Z-AAD-OH
• Synonyms: (S)-2-(Z-AMINO)-HEXANEDIOIC ACID;N-ALPHA-CARBOBENZOXY-L-ALPHA-AMINOHEXANEDOIC ACID;N-ALPHA-CARBOBENZOXY-L-2-AMINOADIPIC ACID;Z-AAD(2)-OH;Z-AAD(ALPHA)-OH;Z-AAD-OH;Z-L-2-AMINOHEXANEDIOIC ACID;Z-HOMOGLU-OH
• CAS NO: 24325-14-2
• Molecular Formula: C₁₄H₁₇NO₆
• Molecular Weight: 295.29
• Mol File: 24325-14-2.mol
• Article Data: 9

Chemical Properties

• Melting Point: 163℃
• Boiling Point: 551.9±50.0 °C(Predicted)
• Appearance: /
• Density: 1.322±0.06 g/cm3(Predicted)
• Storage Temp.: Store at RT.
• PKA: 3.91±0.21(Predicted)
• CAS DataBase Reference: Z-AAD-OH(CAS DataBase Reference)
• NIST Chemistry Reference: Z-AAD-OH(24325-14-2)
• EPA Substance Registry System: Z-AAD-OH(24325-14-2)

Safety Data

• Hazardous Substances Data: 24325-14-2(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Upstream product

• 58456-27-2 (S)-3-(benzyloxycarbonyl)-4-(4-diazo-3-oxobutyl)-5-oxazolidinone 
• 6033-32-5 (S)-2-amino-6-hydroxyhexanoic acid 
• 56-86-0 L-glutamic acid 
• 24325-12-0 (+/-)-2-chloroacetaminohexanedioic acid 
• 1118-90-7 L-homoglutamic acid 
• 501-53-1 benzyl chloroformate 
• 157701-50-3 (2S)-2-amino-5-[(N-methylsulphonyl)carbamoyl]pentanoic acid 
• 749874-26-8 Nα-Z-L-aminoadipic acid-δ-semialdehyde 
• 2212-75-1 N₂-[(benzyloxy)carbonyl]-L-lysine 
• 102922-72-5 (S)-2-(((benzyloxy)carbonyl)amino)-6-hydroxyhexanoic acid 
• 23632-67-9 (S)-3-[3-(benzyloxycarbonyl)-5-oxooxazolidin-4-yl]propanoic acid 

Downstream Products

• 87141-26-2 N-benzyloxycarbonyl-1-(p-nitrobenzyl)-δ-(L-α-aminoadipyl)-S-benzyl-L-cysteine 
• 87147-42-0 N-benzyloxycarbonyl-1-(p-nitrobenzyl)-δ-(L-α-aminoadipyl)-S-benzyl-L-cysteinyl-D-valine 
• 87141-25-1 N-benzyloxycarbonyl-1-(p-nitrobenzyl)-δ-(L-α-aminoadipyl)-S-benzyl-L-cysteine, benzhydryl ester 
• 87141-28-4 N-benzyloxycarbonyl-1-(p-nitrobenzyl)-δ-(L-α-aminoadipyl)-S-benzyl-L-cysteinyl-D-valylglycine, benzyl ester 
• 87141-27-3 N-benzyloxycarbonyl-1-(p-nitrobenzyl)-δ-(L-α-aminoadipyl)-S-benzyl-L-cysteinyl-D-valine, benzhydryl ester 
• 69644-78-6 (S)-2-Amino-5-[(R)-2-[(R)-2-(5-amino-5-carboxy-pentanoylamino)-2-((R)-1-carboxy-2-methyl-propylcarbamoyl)-ethyldisulfanyl]-1-((R)-1-carboxy-2-methyl-propylcarbamoyl)-ethylcarbamoyl]-pentanoic acid 
• 1173377-33-7 N',N''-didodecyl-L-2-(Nα-benzyloxycarbonylamino)adipamide 
• 24325-17-5 N-benzyloxycarbonyl-α-benzylester-δ-L-α-aminoadipic acid 
• 103548-47-6 (S)-benzyl 2-benzyloxycarbonylamino-9-(4-imidazolyl)-7-azanonanoate 
• 84246-49-1 2(S)-2-(benzyloxycarbonylamino)-6-hydroxyhexanoic acid, benzyl ester 
• 87829-74-1 (S)-benzyl 6-oxo-2-benzyloxycarbonylaminohexanoate 
• 78664-73-0 L-pyro-2-aminoadipyl-L-leucyl-L-prolinamide 
• 78664-72-9 L-pyro-2-aminoadipic acid pentafluorophenyl ester 
• 34622-39-4 (2S)-6-oxopipecolic acid 

Relevant articles and documents

Enzymes responsible for the conversion of Nα-[(benzyloxy) carbonyl]-D-lysine to Nα-[(benzyloxy)carbonyl]-D-aminoadipic acid by Rhodococcus sp. AIU Z-35-1

The enzymes responsible for the conversion of Nα- [(benzyloxy)carbonyl]-D-lysine (Nα-Z-D-lysine) to N α-Z-D-aminoadipic acid (Nα-Z-D-AAA) by Rhodococcus sp. AIU Z-35-1 were identified. Nα-Z-D-Lysine was first converted to Nα-Z-D-aminoadipic δ-semialdehyde (Nα-Z-D-AASA) by D-specific amino acid deaminase, whereas Nα-Z-L-lysine was converted to Nα-Z-L-AASA by L-specific amino acid oxidase. The resulting Nα-Z-D-AASA was then converted to Nα-Z-D-AAA by the same aldehyde dehydrogenase that is responsible for Nα-Z-L-AASA oxidation. The product amount of the D-specific amino acid deaminase reached the maximum at one day of cultivation in the L-lysine medium. The aldehyde dehydrogenase reached the maximum at three days of cultivation.

Vinyl sulfide cyclized analogues of angiotensin II with high affinity and full agonist activity at the AT1 receptor

Vinyl sulfide cyclized analogues of the octapeptide angiotensin II that are structurally related to the cyclic disulfide agonist c[Hcy3,5 Ang II have been prepared. The synthesis relies on the reaction of the mercapto group of a cysteine residu

Tricyclic compounds with pharmaceutical activity

The invention relates to tricyclic compounds of formula (I) STR1 wherein R1 is hydrogen, amino, (1-4C)alkyl, (1-4C)alkoxy, hydroxy-(1-4C)alkyl or fluoro-(1-4C)alkyl; R2 is hydrogen, (1-4C)alkyl, (3-4C)alkenyl, (3-4C)alkynyl, hydroxy-(2-4C)alkyl, halogeno-(2-4C)alkyl or cyano-(1-4C)alkyl; Ar is optionally-substituted phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl; and R3 includes a group of the formula --NHCH(CO2 H)--A1 --Y1 wherein A1 is (1-6C)alkylene and Y1 is carboxy, tetrazol-5-yl, N-?(1-4C)alkylsulphonyl!carbamoyl, N(phenylsulphonyl)carbamoyl, tetrazol-5-ylthio, tetrazol-5-ylsulphinyl or tetrazol-5-ylsulphonyl; or pharmaceutically-acceptable salts or esters thereof; to processes for their manufacture; to pharmaceutical compositions containing them; and to their use as anti-cancer agents.